Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) (NCT06912633)
A Randomized, Masked, Sham-Controlled Phase 2 Trial of the Safety of a Single Intravitreal Injection of jCell (Famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.
Who can join: Review the eligibility criteria below.
Location: Associated Retina Consultants — Phoenix, Arizona
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Associated Retina Consultants — Phoenix, Arizona
- California Retina Consultants — Bakersfield, California
- Retina-Vitreous Associates Medical Group — Beverly Hills, California
- Gavin Herbert Eye Institute, UC Irvine — Irvine, California
- Retina Consultants Medical Group — Sacramento, California
- Vitreo Retinal Associates — Gainesville, Florida
- Illinois Retina Associates — Oak Park, Illinois
- NJRetina — Teaneck, New Jersey
- Long Island Vitreoretinal Consultants — Westbury, New York
- Retina Consultants of Texas: Bellaire Retina Center — Bellaire, Texas
- Retina Consultants of Texas: San Antonio — San Antonio, Texas
- The Retina Group of Washington — Fairfax, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Retinitis Pigmentosa
- Natural History of PRPF31 Mutation-Associated Retinal Dystrophy — San Francisco, California
- Prospective Natural History Study of Retinitis Pigmentosa — Pittsburgh, Pennsylvania
- Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) — Beverly Hills, California
- FIGHT-RP 1 Extension Study — Baltimore, Maryland
- Promising ROd-cone DYstrophy Gene therapY — Miami, Florida
Explore by condition: All Retinitis Pigmentosa clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.